Safety and Efficacy of Ultrasound-Enhanced Thrombolysis A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies

• Published in: Stroke (1970) Vol. 41; no. 2; pp. 280 - 287
• Main Authors: Tsivgoulis, Georgios, Eggers, Jürgen, Ribo, Marc, Perren, Fabienne, Saqqur, Maher, Rubiera, Marta, Sergentanis, Theodoros N., Vadikolias, Konstantinos, Larrue, Vincent, Molina, Carlos A., Alexandrov, Andrei V.
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01.02.2010
• Subjects: Aged; Aged, 80 and over; Biological and medical sciences; Brain Ischemia - diagnostic imaging; Brain Ischemia - physiopathology; Brain Ischemia - therapy; Cardiovascular system; Combined Modality Therapy - adverse effects; Combined Modality Therapy - methods; Combined Modality Therapy - statistics & numerical data; Female; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - adverse effects; Humans; Intracranial Thrombosis - diagnostic imaging; Intracranial Thrombosis - physiopathology; Intracranial Thrombosis - therapy; Male; Medical sciences; Middle Aged; Neurology; Pharmacology. Drug treatments; Randomized Controlled Trials as Topic - statistics & numerical data; Thrombolytic Therapy - adverse effects; Thrombolytic Therapy - methods; Thrombolytic Therapy - statistics & numerical data; Tissue Plasminogen Activator - administration & dosage; Tissue Plasminogen Activator - adverse effects; Treatment Outcome; Ultrasonic Therapy - adverse effects; Ultrasonic Therapy - methods; Ultrasonic Therapy - statistics & numerical data; Ultrasonography, Doppler, Transcranial - adverse effects; Ultrasonography, Doppler, Transcranial - methods; Ultrasonography, Doppler, Transcranial - statistics & numerical data; Vascular diseases and vascular malformations of the nervous system; Vasodilator agents. Cerebral vasodilators; Doppler ultrasound study; sonothrombolysis; Stroke; Nervous system diseases; Serine endopeptidases; tissue plasminogen activator; Enzyme; Color; Cardiovascular disease; t-Plasminogen activator; Cerebral disorder; Vascular disease; transcranial color-coded duplex; Peptidases; transcranial Doppler; Central nervous system disease; Hydrolases; Ultrasound; ultrasound-enhancedthrombolysis; Cerebrovascular disease
• ISSN: 0039-2499; 1524-4628; 1524-4628
• DOI: 10.1161/STROKEAHA.109.563304

Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Subjects and Methods— Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD±microspheres (μS), tPA+TCCD±μS, and tPA+low-frequency ultrasound. Results— A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%–11.2%); tPA+TCCD, 11.1% (95% CI, 0%–28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%– 61.4%); and tPA alone, 2.9% (95% CI, 0%–8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%– 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%–24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD±μS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70–5.25; P =0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44–3.60; P =0.67). Conclusions— The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.